Alzheimer's drug that can slow disease gets backing from FDA advisers

A closely watched Alzheimer’s drug from Eli Lilly, donanemab, won unanimous backing from FDA advisers on Monday for its ability to slow mild dementia despite risks such as brain swelling and bleeding, setting the stage for its expected approval later this year.